Under normal conditions, insulin inhibits platelet aggregation by suppressing the P2Y12 pathway in healthy volunteers [51]; however, such antithrombotic protection is hampered in T2DM patients due to reduced insulin sensitivity by platelets [52]. Here, INS is linked to type 2 diabetes mellitus.